Navigation Links
MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM

ALEXANDRIA, Egypt and NORCROSS, Ga., June 22 /PRNewswire/ -- MediPurpose®, a medical device innovation and medical product distribution company, today announced that it has signed an exclusive agreement to distribute advanced wound care products from Egypt-based OEM Pharmaplast.

The milestone agreement is the foundation for MediPurpose's recently launched Wound Care division. For Pharmaplast, it enables access to an expanded market for its products within the Americas while continuing to expand their worldwide presence.

"We are very pleased to announce our exclusive partnership with Pharmaplast," said MediPurpose COO and President Randy Prather, who oversees the Wound Care division. "Their quality and breadth of product line of advanced wound care products is the ideal foundation for our Wound Care division."

The new Wound Care division—and the subsequent agreement with Pharmaplast— spotlights MediPurpose's attention on new business development to expand medical product lines that complement their award-winning medical product distribution services and logistics capabilities.

"Our distribution services capability was a key advantage that MediPurpose was able to offer that cemented the relationship with our new OEM partner," said Prather. "MediPurpose's goal was to provide a quality, comprehensive advanced wound care line that would afford substantial profit opportunities for our existing and new distribution partners who service this market. Pharmaplast provided us the opportunity to meet and exceed those original goals."

"Additionally, with the launch of this new division, we are very excited about the opportunities to expand the division's product capabilities by partnering with additional wound care products manufacturers that offer complementary products in the Americas and abroad."

MediPurpose founder and CEO Patrick Yi added, "It is our responsibility to ensure that all our new medical product lines achieve the same superior product quality and customer service as our current SurgiLance® safety lancet product line. After an exhaustive evaluation, I am confident that our customers will receive the same standard of service from Pharmaplast."

About Pharmaplast

Started in 1985 by three pharmacists, Pharmaplast engages in the manufacture of advanced wound care and immobilization products.

Today, Pharmaplast is a shareholding company with five factories in Egypt that employ 700 employees. All factories are ISO 9001 certified, all products bear the CE mark and most of the products are FDA registered.

Pharmaplast believes that consistent innovation and quality assurance is the key to its survival, and thus invests to generate new products that help medical professionals to provide quality patient care with maximum cost-efficiency.

For more information about Pharmaplast, please visit

About MediPurpose

Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.

Known for its innovation of the SurgiLance® Safety Lancet, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor.

MediPurpose also offers angel funding, medical product development and medical device consulting for medical device inventors and medical product companies seeking entrance or expansion into the medical device markets.

For more information about MediPurpose's medical products, medical distribution channel management services and medical device development services, please visit

SOURCE MediPurpose
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/30/2015)... 30, 2015   Royal Philips (NYSE: ... industry,s first MRI guided user interface and automatic scan ... with MR Conditional implants, such as knee and hip ... Radiological Society of North America Annual Meeting (RSNA) . ... diagnostic confidence of this growing patient population. ScanWise Implant ...
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... Live Very Well is excited to announce ... . The multi-carrier insurance exchange platform offers individual vision and dental ... compare, quote and match plans to meet their needs. , Beginning December ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
(Date:11/30/2015)... ... 30, 2015 , ... Stress, anxiety, illness, infection or even a need for ... , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in ... to tumors. , “Bad headaches that don’t go away, that don’t have ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... ... 30, 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences ... Jurassic to their collection of interactive exhibits within the Kids In Charge! building. In ... guests to get closer than ever to a range of animals as they drink, ...
Breaking Medicine News(10 mins):